User profiles for "author:Philip Bejon"
 | Philip BejonKEMRI-Wellcome Verified email at kemri-wellcome.org Cited by 21613 |
[HTML][HTML] Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis
Background Vitamin D deficiency is associated with non-communicable and infectious
diseases, but the vitamin D status of African populations is not well characterised. We aimed …
diseases, but the vitamin D status of African populations is not well characterised. We aimed …
[HTML][HTML] A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa
L Ndwiga, KM Kimenyi, K Wamae, V Osoti… - International Journal for …, 2021 - Elsevier
Artemisinin resistance (AR) emerged in South East Asia 13 years ago and the identification
of the resistance conferring molecular marker, Plasmodium falciparum Kelch 13 (Pfk13), 7 …
of the resistance conferring molecular marker, Plasmodium falciparum Kelch 13 (Pfk13), 7 …
[HTML][HTML] Oral versus intravenous antibiotics for bone and joint infection
HK Li, I Rombach, R Zambellas… - … England Journal of …, 2019 - Mass Medical Soc
Background The management of complex orthopedic infections usually includes a
prolonged course of intravenous antibiotic agents. We investigated whether oral antibiotic …
prolonged course of intravenous antibiotic agents. We investigated whether oral antibiotic …
[HTML][HTML] Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age
Background Plasmodium falciparum malaria is a pressing global health problem. A previous
study of the malaria vaccine RTS, S (which targets the circumsporozoite protein), given with …
study of the malaria vaccine RTS, S (which targets the circumsporozoite protein), given with …
Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Africa is
poorly described. The first case of SARS-CoV-2 in Kenya was reported on 12 March 2020 …
poorly described. The first case of SARS-CoV-2 in Kenya was reported on 12 March 2020 …
[HTML][HTML] Phase 1 trials of rVSV Ebola vaccine in Africa and Europe
ST Agnandji, A Huttner, ME Zinser… - … England Journal of …, 2016 - Mass Medical Soc
Background The replication-competent recombinant vesicular stomatitis virus (rVSV)–based
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …
[HTML][HTML] Seven-year efficacy of RTS, S/AS01 malaria vaccine among young African children
Background The candidate malaria vaccine RTS, S/AS01 is being evaluated in order to
inform a decision regarding its inclusion in routine vaccination schedules. Methods We …
inform a decision regarding its inclusion in routine vaccination schedules. Methods We …
[PDF][PDF] Upregulation of TGF-β, FOXP3, and CD4+ CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection
M Walther, JE Tongren, L Andrews, D Korbel, E King… - Immunity, 2005 - cell.com
Understanding the regulation of immune responses is central for control of autoimmune and
infectious disease. In murine models of autoimmunity and chronic inflammatory disease …
infectious disease. In murine models of autoimmunity and chronic inflammatory disease …
[HTML][HTML] Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine
DE Neafsey, M Juraska, T Bedford… - … England Journal of …, 2015 - Mass Medical Soc
Background The RTS, S/AS01 vaccine targets the circumsporozoite protein of Plasmodium
falciparum and has partial protective efficacy against clinical and severe malaria disease in …
falciparum and has partial protective efficacy against clinical and severe malaria disease in …
[HTML][HTML] Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure
Background The candidate malaria vaccine RTS, S/AS01E has entered phase 3 trials, but
data on long-term outcomes are limited. Methods For 4 years, we followed children who had …
data on long-term outcomes are limited. Methods For 4 years, we followed children who had …